The CRO concept is alive again! Sinotherapeutical, Heyuan Biotechnology, etc. rose more than 4%

【Pharmaceutical Network Pharmaceutical Stock Market】News on January 13, the concept of CRO is active again, from the perspective of individual stocks, of which Xuantai Pharmaceutical rose by more than 5%, Tailong Pharmaceutical, Heyuan Biotechnology, nearshore protein and so on have followed
suit.
As of 10:34 on January 13, Sinotherapeutics rose 4.
27%, with a quotation of 16.
86 yuan, a turnover of 76.
31 million, a turnover rate of 11.
18%, and a price-to-earnings (TTM) of 54.
20
.
According to the data, Sinotherapeutics is mainly engaged in the research and development, production and sales of high-end generic drugs and CRO services
.
The company's main products are high-end generic drugs and CRO services
.
Sinotherapeutics is committed to the internationalization of pharmaceutical preparations and provides cost-effective pharmaceutical products
for the global market.
At present, the company has successfully developed a number of products approved for marketing in many regions around the world, and the therapeutic fields of research products cover metabolism, anti-tumor, central nervous system, etc
.
According to the analysis, one of the highlights of the stock is that the company's ursodeoxycholic acid capsules are clinically mainly used for the treatment of sterol gallstones, cholestatic liver diseases (such as primary biliary cirrhosis) and bile reflux gastritis
.
As of 10:34 on January 13, Tailong Pharmaceutical rose 1.
15%, quoted 6.
15 yuan, with a turnover of 39.
22 million, a turnover rate of 1.
11%, and a loss in price-to-earnings (TTM
).
According to the data, Tailong Pharmaceutical is a modern pharmaceutical enterprise
integrating production, operation and scientific research, mainly Chinese and Western medicine products, and producing oral liquids, tablets, capsules, APIs and other dosage form products.
At present, the company has a traditional Chinese medicine oral liquid manufacturing center, a western medicine solid dosage manufacturing center, an international level drug research and development and CRO technical service center, etc
.
On the news, the company responded to a series of questions raised by investors on the investor interactive platform on January 12
.
It said that the company's production of Shengmai drink uses red ginseng raw materials, and the upcoming Shengmai drink uses party ginseng raw materials
.
Both have the effect of invigorating qi and rejuvenating, nourishing yin and rejuvenating; At present, the company's compound and oral liquid production lines are in full production, and the production load of Chinese medicine pieces has also increased, making every effort to ensure the production and supply of related epidemic prevention drugs; The company's products such as children's clear heat and cough oral liquid, cough orange red oral liquid, Chuanbei cough lotion and other products have the effect of cough and phlegm, please refer to the drug instructions or use under the guidance of a pharmacist; Tongjuntang, a wholly-owned subsidiary, is fermented to make special pieces and operated Chinese medicine pieces such as almonds, ephedra, chuanbei, licorice, loquat leaves, etc.
, which also have the effect of cough and phlegm; As of the first half of 2022, the revenue of Tongjuntang Chinese medicine pieces business increased by 33.
34% over the same period of the previous year, and the revenue of the circulation business of pharmaceutical and medicinal materials increased by 45.
58% over the same period of the previous year
.
As of 10:34 on January 13, Heyuan Biotech rose 4.
38%, quoted 22.
51 yuan, with a turnover of 7.
8339 million, a turnover rate of 0.
48%, and a price-to-earnings (TTM) of 187.
82
.
According to the data, Heyuan Biotech is a biotechnology company focusing on the field of gene therapy, focusing on providing CRO services such as gene therapy vector development, gene function research, drug target and efficacy research for basic research of gene therapy, and CDMO services
such as process development and testing, IND-CMC pharmaceutical research, and GMP production of clinical samples for the research and development of gene drugs.
On the news, the company recently announced that the net repayment for three consecutive days accumulated 4.
5331 million yuan
.
As of 10:34 on January 13, nearshore protein rose 4.
27%, the quotation was 86.
06 yuan, the turnover was 53.
03 million, the turnover rate was 3.
81%, and the price-to-earnings (TTM) was 54.
26
.
According to the data, nearshore protein is deeply engaged in the recombinant protein industry, and the company provides one-stop CRO services
from product to technological innovation and development for downstream customers based on a perfect technical system and self-produced innovative raw materials.
The company's main business is raw materials and technical solutions in the fields of biological drugs, in vitro diagnostics, mRNA vaccine drugs, and basic research of life sciences, including the research and development, production and sales of target and factor proteins, recombinant antibodies, enzymes and reagents and related technical services
.
Recently, the company announced that the net repayment of financing for 6 consecutive days accumulated 10.
7812 million yuan
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.